H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic Strategies
C. Terranova, M. Maitituoheti, A. T. Raman…·K. Rai
The paper identifies H3K4me1-marked enhancers in therapy-resistant prostate cancers and suggests SOX4 and MENIN inhibition as therapeutic strategies.